Results 161 to 170 of about 697,307 (264)
Impact of technological acceptance on application-based engagement among type 2 diabetes patients: local insights and implications for developing countries. [PDF]
Tahira A +4 more
europepmc +1 more source
Intratumour heterogeneity complicates precision management of advanced endometrial cancer. Circulating tumor DNA (ctDNA) offers a minimally invasive strategy to capture tumor evolution and therapeutic resistance. Here, we compare tumor‐agnostic NGS with tumor‐informed ddPCR, outlining their relative sensitivity, concordance, and clinical implications ...
Carlos Casas‐Arozamena +15 more
wiley +1 more source
Gait Retraining for Patellofemoral Pain in Runners: An Umbrella Review of Clinical and Biomechanical Evidence. [PDF]
Petri AC +6 more
europepmc +1 more source
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
Skeletal muscle overuse injury: pathophysiological mechanisms, molecular pathways, and rehabilitation strategies. [PDF]
Wu G, Li N.
europepmc +1 more source
A urine‐based digital PCR assay targeting two hotspot TERT promoter variants detected bladder cancer with high sensitivity and no false positives in this case–control cohort. The streamlined AbsoluteQ workflow outperformed Sanger sequencing and supports non‐invasive molecular testing for bladder cancer detection.
Anna Nykel +12 more
wiley +1 more source
The High Solid Loading and Stability of SiO<sub>2</sub> Ceramic Slurry for Stereolithography. [PDF]
Zhang W, Huang C, Xia S, Hu X, Li Q.
europepmc +1 more source
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source

